MS Drug's immune impact revealed in small study
NCT ID NCT06415864
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how the oral medication cladribine changes different types of immune cells in people with relapsing-remitting multiple sclerosis (RRMS). Ten participants provided blood and spinal fluid samples over 96 weeks to track changes in B cells, T cells, and other immune markers. The goal was to better understand how cladribine works in the body, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Barts Health NHS Trust
London, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we decode the different types of pain in multiple sclerosis?
- Can a blood pressure pill slow MS disability?
- Hidden MS progression: can brain scans and blood tests predict it?
- Can Brain-Training apps fix sleep in MS?
- Can an Iron-Based dye reveal hidden inflammation in progressive MS?
- Strumming for the brain: could ukulele lessons sharpen minds in MS?